Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "CX3CR1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
CX3C chemokine receptor 1 (CX3CR1) also known as the fractalkine receptor or G-protein coupled receptor 13 (GPR13) is a protein that in humans is encoded by the CX3CR1 gene. As the name suggests, this receptor binds the chemokine CX3CL1 (also called neurotactin or fractalkine).
Methods of treating and diagnosing diabetes with cx3cr1 modulators
InactiveUS20060160076A1Peptide/protein ingredientsGenetic material ingredientsCX3CR1Insulin resistance
The present invention provides compositions and methods for diagnosing and treating diabetes and insulin resistance. In particular, the invention provides methods of identifying modulators of CX3CR1 and using those modulators to treat diabetes, as well as methods of diagnosing diabetes by measuring the levels of CX3CR1 or fractalkine in a patient.
Owner:MEATABOLEX
Method to diagnose or screen for inflammatory diseases
The invention relates to the field of medical diagnostics. More specifically, the invention relates to methods to diagnose or screen for inflammatory conditions or disease, including auto-inflammatory disease and affective disorder, in a subject, preferably a human subject, by assaying for a marker for an inflammatory disease. Provided is a method to diagnose, screen for or predict the development of an affective disorder (AD), preferably bipolar disorder (BP), in a subject, the method comprising determining the level of at least one, preferably at least two, more preferably at least three, most preferred at least four, AD-specific gene product(s) in a biological sample isolated from the subject, preferably peripheral blood monocytes, wherein the gene is selected from the group comprising ATF3, phosphodiesterase 4 B, CXCL2, BCL2-related protein A2, Dual specificity phosphatase 2, TNFα-induced protein 3 / A20, BTEB1 CXCL3, Chemokine CCL-3 like, CCL-4, CCL20, CX2CR1, Amphiregulin, Thrombomodulin, Heparin-binding EGF-like growth factor, DNA-damaged inducible transcript, V28 chemokine-like receptor, TRAIL. MAPK6, B4BP4, PBEF1, Thrombospondin 1, MAFF, HSP70, CCL2, MCP-3, CCR2, CX3CR1, DOK1, HBB, G-gamma globin, THBD, PHLDA1, DTR and GNLY.
Owner:ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC
Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
Owner:AZIENDE CHIMHE RIUNITE ANGELINI FRANCESCO A C R A F
Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.
Owner:EISIA R&D MANAGEMENT CO LTD
1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1
Owner:AZIENDE CHIMHE RIUNITE ANGELINI FRANCESCO A C R A F
TLR4 (Toll-like receptor) compound of targeting microglia as well as preparation method and application of compound
InactiveCN103933580AIncrease uptakeHigh transfection efficiencyNervous disorderGenetic material ingredientsCX3CR1Antiinflammatory drug
The invention discloses a TLR4 (Toll-like receptor) compound of targeting microglia as well as a preparation method and application of the compound in the pharmaceutical field, and belongs to the field of biomedicine. The compound is formed by binding fusion peptide of Q9 peptide (QQQKKKKKK) and T9 peptide (LTQQVVMKF) and TLR4RNAi through an electrostatic interaction; through a guiding function of the Q9 peptide, the compound can specifically target a specific CX3CR1 receptor on the surface of the microglia; when the T9 peptide acts with the CX3CR1 receptor, the TLR4RNAi is efficiently transfected into the microglia to inhibit activation of the microglia, so as to inhibit an inflammatory reaction after microglia mediated cerebral hemorrhage; the compound can be used for preparing microglia mediated anti-inflammatory drugs, and has good development and application prospects in the field of cerebral hemorrhage treatment.
Owner:中国人民解放军南京军区福州总医院四七六医院
1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
Owner:AZIENDE CHIMHE RIUNITE ANGELINI FRANCESCO A C R A F
Targeting polypeptide-gene composite as well as preparation method and application of composite
InactiveCN103007293ADoes not affect natural activityInhibitionOrganic active ingredientsNervous disorderDiseaseNervous system
The invention discloses a targeting polypeptide-gene composite. The composite is formed by a binding fusion protein of HIV-Tat (49-57) peptide (RKKRRQRRR) (Human Immunodeficiency Virus Trans-activator of Transcription) and V9 peptide (LTQQMKFVV) and an HIF-1alphashRNA (Hypoxia Inducible Factor-1alpha Short Hairpin Ribonucleic Acid) carrier by means of electrostatic interaction; the composite can use the guide effect of the V9 (CX3C-chemokine receptor 1) receptor on the surface of microglia, and, at the same time when the V9 peptide and the CX3CR1 receptor act with each other, the HIF-1alphashRNA is efficiently transfected into the microglia to interfere with the HIF-1alpha (Hypoxia Inducible Factor-1alpha) expression and inhibit the microglia activation so as to further inhibit the occurrence and progression of a microglia-mediated central nervous system disease. The composite can be applied to the preparation of a medicine for treating the microglia-mediated central nervous system disease and has good development and application prospect in the field of treating the nervous system disease.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
Owner:AZIENDE CHIMHE RIUNITE ANGELINI FRANCESCO A C R A F
1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1 and CX3CR1
Owner:AZIENDE CHIMHE RIUNITE ANGELINI FRANCESCO A C R A F
Modulators of the cx3cri receptor and therapeutic uses thereof
InactiveUS20120141538A1Low cost productionReduced activityOrganic active ingredientsPeptide/protein ingredientsImmunologic disordersAdjuvant
The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.
Owner:UNIV PIERRE & MARIE CURIE
Prognostic biomarkers for influenza
InactiveUS20150376723A1Peptide librariesMicrobiological testing/measurementControl levelH1N1 influenza
Described are biomarkers and associated methods for identifying a subject having, or at risk of developing, severe illness from influenza. The level of one or more biomarkers in a test sample from the subject is determined and compared to a control level. Optionally, the subject has or is suspected of having H1N1 influenza. In some embodiments the biomarkers may include IL23R, IL10, TNFRSF13B, CX3CR1, CCR2, MAP2K3 and / or IRF1. In some embodiments, the biomarkers include a combination of IL2 and IL23R or IL10 and IL23R. Also described are methods which include determining the level of two or more biomarkers in a sample and multivariate methods are used for comparing the levels in the test sample to the level in a control sample.
Owner:UNIV HEALTH NETWORK
CX3CR1 Small Molecule Antagonists, and Methods Using Same
The invention provides compounds that are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and / or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and / or coronary artery disease), and / or multiple sclerosis.
Owner:DREXEL UNIV
MiR-3OB (Micro-Ribonucleic Acid-30b) composite for targeting microglia as well as preparation method and application of composite
InactiveCN103007292AIncrease uptakeInhibition of activationOrganic active ingredientsNervous disorderDiseaseCX3CR1
The invention discloses a miR-3OB (Micro-Ribonucleic Acid-30b) composite of targeting microglia. The composite is formed by binding a fusion peptide of K9 peptide (KKKKKKKKK) and S9 peptide (VVMKFLTQQ) and the miR-30b by means of electrostatic interaction; the composite can use the guide effect of the S9 peptide to specifically target a specific CX3CR1 receptor on the surface of the microglia, and at the same time when the S9 peptide and the CX3CR1 receptor act with each other, the miR-30b is efficiently transfected into the microglia to inhibit the microglia activation so as to further inhibit the occurrence and progression of a microglia-mediated central nervous system disease. The composite can be applied to the preparation of a medicine for treating the microglia-mediated central nervous system disease and has good development and application prospect in the field of treating the nervous system disease.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
Diagnostic methods and compositions for cancer immunotherapy
PendingCN113260633AOrganic active ingredientsAntibody mimetics/scaffoldsAntiendomysial antibodiesAntigen Binding Fragment
Owner:F HOFFMANN LA ROCHE & CO AG
Methods and compositions for reconstituting microglia
PendingUS20220323503A1Reduce probabilityOrganic active ingredientsNervous disorderCX3CR1Polynucleotide
The present disclosure features CX3CR1 hemizygous and / or homozygous defective cells and methods of using such cells for the treatment of a metabolic or neurological disorder. The disclosed methods include methods for making and modifying CX3CR1 hemizygous and / or homozygous defective cells, such as hematopoietic stem progenitor cells. Other disclosed methods include methods of treating a subject having or suspected of having a metabolic or neurological disease comprising administering to the subject a composition comprising a hemizygous and / or homozygous defective CX3CR1 cell. The CX3CR1 hemizygous and / or homozygous defective cell may be modified to have a nucleic acid molecule encoding a therapeutic polypeptide or polynucleotide.
Owner:CHILDRENS MEDICAL CENT CORP +1
Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1
ActiveUS11339183B2More efficaciousToxic reductionNervous disorderAntipyreticIntestinal tract diseasesAutoimmune condition
![Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5ef08fce-c133-4565-a1eb-fd4c54f53c29/US11339183-C00001.png "Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1")
![Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5ef08fce-c133-4565-a1eb-fd4c54f53c29/US11339183-C00002.png "Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1")
![Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5ef08fce-c133-4565-a1eb-fd4c54f53c29/US11339183-C00003.png "Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1")
Owner:KANCERA AB
Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction
InactiveUS8518401B1Inhibited iNOS productionImprove pathological conditionsOrganic active ingredientsAntipyreticCX3CR1Antagonist
A therapeutic agent for an inflammatory disease comprising an antibody or a CX3CR1 antagonist that inhibits an interaction of fractalkine and CX3CR1 is provided.
Owner:EISIA R&D MANAGEMENT CO LTD
CX3CR1 gene humanized non-human animal as well as construction method and application thereof
ActiveCN112553213ACompounds screening/testingReceptors for cytokines/lymphoines/interferonsBiotechnologyImmunologic disorders
The invention provides a construction method of a CX3CR1 gene humanized non-human animal. The nucleotide sequence for encoding a human CX3CR1 protein is introduced into a non-human animal genome in ahomologous recombination manner, the humanized CX3CR1 protein can be normally expressed in the animal body, the animal body can be used as an animal model for human CX3CR1 signal mechanism research and tumor and immune disease drug screening, and the important application value is realized on the research and development of new drugs of immune targets. The invention also provides a humanized CX3CR1 protein, a humanized CX3CR1 gene, a targeting vector of the CX3CR1 gene, the non-human animal obtained with the construction method and an application of the non-human animal in the field of biological medicines.
Owner:BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD
Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1
PendingUS20210292349A1More efficaciousToxic reductionNervous disorderAntipyreticIntestinal tract diseasesAutoimmune condition
There is provided a compound of formula (I), wherein R1, R2, Q1 and formula (X) are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and / or CX3CL1, in particular acute and / or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and / or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
![Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/8098dfd2-8b29-48bd-a8b7-7ab8db9d1fcd/US20210292349A1-C00001.png "Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1")
![Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/8098dfd2-8b29-48bd-a8b7-7ab8db9d1fcd/US20210292349A1-C00002.png "Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1")
![Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/8098dfd2-8b29-48bd-a8b7-7ab8db9d1fcd/US20210292349A1-C00003.png "Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1")
Owner:KANCERA AB
Methods and compositions for regulation of neurological conditions
InactiveUS20100215663A1Inhibiting initiationAvoid maintenanceCompound screeningNervous disorderCX3CR1Cell biology
Owner:NORTHWESTERN UNIV
Novel Target for Diagnosis and Treatment of Diabetes and Cardiovascular Diseases
InactiveUS20140357556A1Improve diabetesLower blood sugar levelsPeptide/protein ingredientsMetabolism disorderCX3CR1Medicine
Diagnostic, prognostic, and treatment methods, compositions, and kits for enhancing insulin secretion and beta cell numbers and functions, and controlling glycemia associated with diabetes, obesity, atherosclerosis, stroke, myocardial infarction, and other cardiovascular diseases, by modulating FKN / CX3CR1 expression levels or activities, and its downstream signaling pathways in a subject in need or at risk.
Owner:RGT UNIV OF CALIFORNIA
Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
Owner:AZIENDE CHIMHE RIUNITE ANGELINI FRANCESCO A C R A F
Methods and compositions for reconstitution of small glial cells
The present disclosure features CX3CR1 hemizygous and / or homozygous deficient cells and methods of using such cells for the treatment of metabolic or nervous system disorders. The disclosed methods include methods for preparing and modifying CX3CR1 hemizygous and / or homozygous deficient cells, such as hematopoietic stem progenitor cells. Other disclosed methods include methods of treating a subject suffering from or susceptible to a metabolic disease or a neurological disease, comprising administering to the subject a composition comprising hemizygous and / or homozygous deficient CX3CR1 cells. The CX3CR1 hemizygous and / or homozygous deficient cells may be modified to have a nucleic acid molecule encoding a therapeutic polypeptide or polynucleotide.
Owner:CHILDRENS MEDICAL CENT CORP +1
Cx3cr1 gene humanized non-human animal and its construction method and application
ActiveCN112553213BCompounds screening/testingReceptors for cytokines/lymphoines/interferonsDiseaseHumanin
Owner:BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD
Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
ActiveUS10815285B2Reduce and preventChemokinesPeptide/protein ingredientsAdenoassociated virusReceptor
Owner:UNIV OF SOUTH FLORIDA +1
tlr4 complex targeting microglial cells and its preparation method and application
InactiveCN103933580BIncrease uptakeDoes not affect natural activityNervous disorderGenetic material ingredientsTreatment fieldBiological activation
Owner:中国人民解放军南京军区福州总医院四七六医院
![Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/958bb42d-9e9a-436a-880d-e9d1e770431a/US11267817-D00001.png "Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists")
![Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/958bb42d-9e9a-436a-880d-e9d1e770431a/US11267817-D00002.png "Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists")
![Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/958bb42d-9e9a-436a-880d-e9d1e770431a/US11267817-D00003.png "Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists")
miR-21 compound of target microglial cell and preparation method and application of miR-21 compound
InactiveCN103028121BIncrease uptakeHigh transfection efficiencyNervous disorderGenetic material ingredientsDiseaseCX3CR1
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
Diagnostic methods and compositions for cancer immunotherapy
PendingUS20210301023A1Improve responsivenessResponsiveness to treatmentOrganic active ingredientsAntibody mimetics/scaffoldsAntiendomysial antibodiesAntigen Binding Fragment
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The compositions and methods described herein can be used, for example, to determine the propensity of a patient to benefit from treatment with a PD-L1 axis binding antagonist and to treat such patients accordingly. Using the compositions and methods of the disclosure, a patient, such as a human cancer patient, may be determined to be likely to benefit from treatment with a PD-L1 axis binding antagonist if the patient exhibits an elevated pre-treatment expression level of one or more of CST7, NKG7, GZMH, MT-ND4, HLA-H, CCL5, CD8A, CMC1, CD8B, HCST, MT-CYB, MT-ND4L, KLRG1, MT-CO2, MT-ATP6, PLEK, CTSW, HLA-C, LYAR, LITAF, GZMB, KLRD1, FGFBP2, KLRC4-KLRK1, KLRK1, B2M, GZMA, ID2, CX3CR1, PRSS23, GNLY, PRF1, and PATL2. Exemplary PD-L1 axis binding antagonists that may be used in conjunction with the compositions and methods of the disclosure are PD-L1 binding antagonists, such as anti-PD-L1 antibodies and antigen-binding fragments thereof, including atezolizumab, as well as PD-1 binding antagonists, such as anti-PD-1 antibodies and antigen-binding fragments thereof.
Owner:GENENTECH INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com